Eli Lilly & Co. and Novo Nordisk A/S have struck a deal with the Trump administration to lower prices for their popular weight-loss drugs, Zepbound and Wegovy, while gaining tariff relief and expanding Medicare access. This agreement aims to increase availability for older Americans.
In a groundbreaking move, the Trump administration has announced new agreements with Novo Nordisk and Eli Lilly to significantly reduce the cost of GLP-1 medications for American patients, including those on Medicare. With prices set to drop dramatically, millions will soon benefit from affordable access to essential treatments.
In a groundbreaking move, President Trump has negotiated significant price reductions for popular weight loss medications, bringing costs down to as low as $50 per month for eligible patients. Find out how these changes will affect access to essential treatments!
In a groundbreaking move, President Trump announces deals with Eli Lilly and Novo Nordisk to reduce obesity drug prices, making treatments more accessible for millions of Americans. Medicare coverage for GLP-1 drugs starts in 2026, changing the landscape of obesity treatment.
As demand for weight loss and diabetes drugs surges, Eli Lilly and Novo Nordisk dominate the market. Discover the challenges, competition, and future of this booming industry.
Eli Lilly's stock surged 3.9% after an outstanding Q3 earnings report, surpassing analysts' expectations with $7.02 per share and $17.6 billion in sales. The company raised its yearly guidance, signaling strong growth potential.
Eli Lilly's third-quarter results exceeded estimates, driven by strong demand for Zepbound and Mounjaro. The company raised its revenue forecast, fueling a 5% rise in shares. Discover how Eli Lilly is maintaining its lead in the competitive obesity drug market.
Pfizer's unexpected deal with the Trump administration on drug pricing sends shockwaves through the pharmaceutical industry, pressuring competitors to follow suit amidst potential regulatory threats. What’s next for drug prices?
Eli Lilly announces a groundbreaking $5 billion investment in a new manufacturing plant near Richmond, aimed at boosting U.S. production of essential pharmaceutical ingredients.
In a day marked by significant market movements, EchoStar's stock skyrocketed following AT&T's $23 billion purchase of wireless licenses. Eli Lilly also saw gains with promising diabetes drug results, while Nvidia's upcoming report looms large.